Subscribe
23 August 2017Americas

CRISPR Therapeutics teams up with Massachusetts hospital in cancer treatment drive

Gene-editing company CRISPR Therapeutics has partnered with the cancer centre at Massachusetts General Hospital to develop T cell therapies for treating the disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
UC, Berkeley files brief in CRISPR Federal Circuit case
31 July 2017   The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.
Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
UC, Berkeley files brief in CRISPR Federal Circuit case
31 July 2017   The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.

More on this story

Americas
CRISPR Therapeutics unites with ViaCyte to treat diabetes
19 September 2018   Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.
Americas
UC, Berkeley files brief in CRISPR Federal Circuit case
31 July 2017   The University of California, Berkeley has filed a brief at the US Court of Appeals for the Federal Circuit in its appeal against a patent decision on the CRISPR/Cas9 technology.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility